Bo-Syuan Lin

Mr. Bo-Syuan Lin

Student - Master's Student - National YANG MING CHIAO TUNG University, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YYYi-Fang Yang
Yi-Fang Yang
HCHao-Wen Chuang
Hao-Wen Chuang
WKWei-Ting Kuo
Wei-Ting Kuo
BLBo-Syuan Lin
Bo-Syuan Lin
Yu-Chan ChangYu-Chan Chang
Yu-Chan Chang
Urothelial cancer is a malignant tumor with metastatic ability and high mortality. Malignant tumors of the urinary system include upper tract urothelial cancer and bladder cancer. In addition to typical genetic alterations and epigenetic modifications, metabolism-related events also occur in urothelial cancer. This metabolic reprogramming includes aberrant expression levels of genes, metabolites, and associated networks and pathways. In this review, we summarize the dysfunctions of glycolytic enzymes in urothelial cancer and discuss the relevant phenotype and signal transduction. Moreover, we describe potential prognostic factors and risks to the survival of clinical cancer patients. More importantly, based on several available databases, we explore relationships between glycolytic enzymes and genetic changes or drug responses in urothelial cancer cells. Current advances in glycolysis-based inhibitors and their combinations are also discussed. Combining all of the evidence, we indicate their potential value for further research in basic science and clinical applications.

Verified
Journal Article
Open access
PDF file
YYYi-Fang Yang
Yi-Fang Yang
CLChien-Hsiu Li
Chien-Hsiu Li
HCHuei-Yu Cai
Huei-Yu Cai
BLBo-Syuan Lin
Bo-Syuan Lin
Cheorl-Ho KimCheorl-Ho Kim
Cheorl-Ho Kim
Yu-Chan ChangYu-Chan Chang
Yu-Chan Chang
Cellular metabolism governs the signaling that supports physiological mechanisms and homeostasis in an individual, including neuronal transmission, wound healing, and circadian clock manipulation. Various factors have been linked to abnormal metabolic reprogramming, including gene mutations, epigenetic modifications, altered protein epitopes, and their involvement in the development of disease, including cancer. The presence of multiple distinct hallmarks and the resulting cellular reprogramming process have gradually revealed that these metabolism-related molecules may be able to be used to track or prevent the progression of cancer. Consequently, translational medicines have been developed using metabolic substrates, precursors, and other products depending on their biochemical mechanism of action. It is important to note that these metabolic analogs can also be used for imaging and therapeutic purposes in addition to competing for metabolic functions. In particular, due to their isotopic labeling, these compounds may also be used to localize and visualize tumor cells after uptake. In this review, the current development status, applicability, and limitations of compounds targeting metabolic reprogramming are described, as well as the imaging platforms that are most suitable for each compound and the types of cancer to which they are most appropriate.